Navigation Links
Groupe Athena, Inc. Clarifies Previous Guidance, Addresses U.S. Drug Shortage
Date:3/2/2012

MUMBAI, India, March 2, 2012 /PRNewswire/ -- Groupe Athena, Inc. (Pink sheets GATA.PK)

The guidance contained below represents forecasts, which indicate possible outcomes and are provided to assist investors with the development of earnings estimates.  While Groupe Athena, Inc. believes that these forecasts represent the best estimate of management as to future events, actual events may differ from these forecasts, and such differences could be material.  These forecasts are subject to risks identified under "Safe Harbor Statement" below.

Groupe Athena, Inc. (Pink sheets GATA.PK) has previously announced they have approximately $60 million in customer orders that they are processing and they expect to be able to convert at least two thirds or approximately $40 million into revenue for the current fiscal year. The company is extremely pleased to issue this guidance update and announce that due to several factors including additional order flow and the recent equipment acquisitions, revenue should increase at least 10% or a minimum of $4 million. Earnings are also expected to increase similarly.  

The company also announced they are in talks with several regional drug manufacturers as part of an effort to help alleviate the recently announced severe, potentially life threatening shortage of vital cancer drugs in the United States including methatrexate, one of the most widely used. The company expects developments in the near term and has committed to make every effort to "fast track" any trials or regulatory filings necessary.

The Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

About Groupe Athena, Inc.

Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 16 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com.

For more information contact:
Paul Cornell
Corporate Shareholder Relations, Inc.
pcornell@totalpublicrelations.com

Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.


'/>"/>
SOURCE Groupe Athena, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Groupe Athena, Inc. Profits Soar on Record Revenues
2. Groupe Athena, Inc. Provides Guidance on Current Orders
3. Groupe Athena, Inc. Clarifies Previous Guidance
4. Groupe Athena, Inc. Reports Record First Quarter Revenues
5. Publicis Healthcare Communications Group Redefines Publicis Groupes Healthcare Client Offering by Joining Forces with Digitas Health and Razorfish Health
6. Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
7. BioCryst Clarifies Government Declaration Regarding Peramivir
8. Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
9. Aethlon Medical Clarifies News Report
10. Decision Diagnostic Corp. Clarifies 10% Stock Dividend, Announces Patent Enforcement Strategy
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... February 20, 2017 The ... anticipated to reach USD 1.4 billion by 2022, ... Research, Inc. Constant evaluation of various techniques by ... to drive growth in this market. Moreover, shunt ... of novel and improved shunts in order to ...
(Date:2/20/2017)... COTTAGE, New York , February 20, 2017 /PRNewswire/ ... a regularized absorption of calcium and phosphorous minerals in ... role of vitamin D ingredients in maintaining a healthy ... or medicines containing vitamin D ingredients is growing in ... the advantage of consuming vitamin D ingredients for treatment ...
(Date:2/19/2017)... --  AC Group Inc. , a leading company, specializing ... the PMS/EHR healthcare marketplace, will exhibit the 7 Stages ... in this ecosystem at HIMSS,17. ... over 200 ACOs, compared and analyzed an ACO,s needs ... are providing different pieces of Population Health technologies designed ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... 2017 , ... Chuck E. Cheese’s® and Center for Autism and Related Disorders ... E. Cheese’s locations throughout New England, New York and New Jersey to provide children ... fun of visiting Chuck E. Cheese’s in a sensory-friendly environment. , After a ...
(Date:2/19/2017)... ... , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... logo with a glitch reveal in just a few clicks of a mouse. Customizable glitch ... each preset. Use these presets to add a uniquely animated logo to any photos or ...
(Date:2/18/2017)... ... 2017 , ... Butler Mobility invited Ken Matthews to visit its manufacturing facility ... Ken was impressed with the safety and reliability of the Stannah Stairlift as well ... This endorsement by Ken Matthews can be heard on News Radio WHP 580 ...
(Date:2/17/2017)... ... , ... Smiles by Seese is a comprehensive family dental practice ... the practice as a skilled and highly credentialed dentist who is qualified to perform ... of all ages with excellence in general, restorative, and cosmetic dentistry . Their ...
(Date:2/17/2017)... (PRWEB) , ... February 17, ... ... Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. 22, 2017 — ... are the critical reimbursement questions manufacturers should be asking before selecting an ...
Breaking Medicine News(10 mins):